About: Impact of COVID-19 on global hepatitis C elimination efforts

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Impact of COVID-19 on global hepatitis C elimination efforts Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Impact of COVID-19 on global hepatitis C elimination efforts
Creator	Zeuzem, Stefan Aghemo, Alessio Ba, Siya Blach, Sarah Cai, Zongzhen Craxi, Antonio Dugan, Ellen Estes, Chris Gamkrelidze, Ivane Kondili, Loreta Ma, Jean Pawlotsky, Devin Razavi, Razavi-Shearer, Homie
source	Elsevier; Medline; PMC
abstract	BACKGROUND & AIMS: COVID-19 has placed significant strain on national healthcare systems at a critical moment in the context of hepatitis elimination. Mathematical models can be used to evaluate the possible impact of programmatic delays on hepatitis disease burden. The objective of this analysis was to evaluate the incremental change in hepatitis C liver-related deaths and liver cancer, following a 3-month, 6-month, or 1-year hiatus in hepatitis elimination program progress. METHODS: Previously developed models were adapted for 110 countries to include a status quo or “no delay” scenario and a “1-year delay” scenario assuming significant disruption in interventions (screening, diagnosis and treatment) in the year 2020. Annual, country-level, model outcomes were extracted, and weighted averages were used to calculate regional (WHO and World Bank Income Group) and global estimates from 2020 to 2030. The incremental annual change in outcomes was calculated by subtracting the “no-delay” estimates from the “1-year delay” estimates. RESULTS: The “1-year delay” scenario resulted in 44,800 (95% UI: 43,800 – 49,300) excess hepatocellular carcinoma (HCC) cases and 72,300 (95% UI: 70,600 – 79,400) excess liver-related deaths (LRDs), relative to the “no delay” scenario globally, from 2020-2030. Most missed treatments would be in lower-middle income countries, while most excess HCC and LRDs would be among high-income countries. CONCLUSIONS: The impact of COVID-19 extends beyond the direct morbidity and mortality associated with exposure and infection. In order to mitigate the impact on viral hepatitis programming and reduce excess mortality from delayed treatment, policy makers should prioritize hepatitis programs as soon as it becomes safe to do so.
has issue date	2020-08-07(xsd:dateTime)
bibo:doi	10.1016/j.jhep.2020.07.042
bibo:pmid	32777322
has license	no-cc
sha1sum (hex)	27a1441263feae84bf24ae10ba97fcc18beef1b1
schema:url	https://doi.org/10.1016/j.jhep.2020.07.042
resource representing a document's title	Impact of COVID-19 on global hepatitis C elimination efforts
has PubMed Central identifier	PMC7411379
has PubMed identifier	32777322
schema:publication	J Hepatol
resource representing a document's body	covid:27a1441263feae84bf24ae10ba97fcc18beef1b1#body_text
is schema:about of	named entity 'Journal' named entity 'COVID-19' named entity 'World Bank' named entity 'Pharco' named entity 'Microsoft Excel' named entity 'Financial support' named entity 'sensitivity analysis' named entity 'research funding' named entity 'AbbVie Inc.' named entity 'Alfasigma' named entity 'Oracle' named entity 'liver cancer' named entity 'Gilead' named entity 'morbidity' named entity 'Vaccine' named entity 'morbidity' named entity 'hepatitis' named entity 'WHO' named entity 'Merck' named entity 'Gilead' named entity 'disease burden' named entity 'hepatitis' named entity 'HCV' named entity 'all-cause mortality' named entity 'Gilead' named entity 'COVID-19' named entity 'GSK' named entity 'Horizontally acquired' named entity 'scenario modeling' named entity 'AbbVie' named entity 'COVID-19' named entity 'Global Burden of Disease' named entity 'Impact Modeling' named entity '1/2' named entity 'Financial support' named entity 'MSD' named entity 'hepatitis' named entity 'HCV' named entity 'Novartis' named entity 'Gilead' named entity 'Allergan' named entity 'MSD' named entity 'June 8' named entity 'Merck' named entity 'HCV' named entity 'United States of America' named entity 'Siemens Healthcare' named entity 'AbbVie' named entity 'Markov model' named entity 'Gilead' named entity 'hepatocellular carcinoma' named entity 'viral hepatitis' named entity 'hepatitis' named entity 'Gilead' named entity 'Astra-Zeneca' named entity 'Gilead' named entity 'Vaccines' named entity 'hepatitis' named entity 'viral hepatitis' named entity 'hepatitis' named entity 'mother-to-child transmission' named entity 'hepatitis' named entity 'Mylan' named entity 'weighted averages' named entity 'antiviral treatment' named entity 'AbbVie' named entity 'AbbVie' named entity 'AbbVie Inc.'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software